Supporting information
Crystallographic Information File (CIF) https://doi.org/10.1107/S0108270106045197/fa3046sup1.cif | |
Structure factor file (CIF format) https://doi.org/10.1107/S0108270106045197/fa3046Isup2.hkl | |
Portable Document Format (PDF) file https://doi.org/10.1107/S0108270106045197/fa3046sup3.pdf |
CCDC reference: 632931
Compound (I) was prepared by the published procedure for cis-Pt(amine)2I2 complexes (Souchard et al., 1990) using 3-acetylpyridine as a ligand [yield 75%; m.p. (decomposition) 523–528 K]. Yellow crystals suitable for X-ray crystallography were obtained by recrystallization from dichloromethane.
The structure was solved by direct methods with SHELXS97 (Sheldrick, 1997) and refined against all data by full-matrix least-squares techniques on F2 using SHELXL97 (Sheldrick, 1997). All non-H atoms were refined anisotropically. H atoms were placed in idealized positions on C atoms, with C—H = 0.93 and 0.96 Å for aromatic and methyl H atoms, respectively. PLATON (Spek, 2003) was used to check missing symmetry or voids in the structure. None was found.
The anticancer drug cisplatin, cis-Pt(NH3)2Cl2, and a few other platinum agents are widely used in the clinical treatment of testicular, ovarian, bladder, head and neck tumors (Farrell, 1989; O'Dwyer et al., 1999). Structure–activity rules that emerged from early studies include the assessment that trans complexes are therapeutically inactive, as opposed to cis complexes – a rule based mainly on the lack of activity for transplatin. Some exceptions from this paradigm were found in 1989, including trans-Pt(pyridine)2Cl2 (Farrell et al., 1989), which is even active towards leukemia L1210 cisplatin-resistant cell lines (Van Beusichem & Farrell, 1992). A review of the cytotoxicity of trans-platinum complexes has been published recently (Natile & Coluccia, 2001).
Platinum–pyridine derivative compounds not only gained interest because of this rule-breaking finding, but also due to the recently reported anticancer complex cis-PtCl2(NH3)(2-picoline) (AMD473) (Chen et al., 1998; Holford et al., 1998). This compound, active both via oral administration and injection, is currently in phase II clinical trials. Other than AMD473 itself and its trans-isomer (McGowan et al., 2005), recent studies involving platinum complexes containing pyridine derivatives (Ypy) include Pt(ESDT)(Ypy)(NH3)Cl (Marzano et al., 2002, 2004; Giovagnini et al., 2005), in which the ethylsarcosinedithiocarbamate ligand (ESDT) is used to reduce nephrotoxic effects, Pt(OAc)2(Ypy)2 and Pt(OAc)2(Ypy)(NH3) (Ma et al., 2005; Quiroga et al., 2006), in which the acetate ligands were used in order to obtain water-soluble complexes, and trans-PtCl2(4-pic)L (Najajreh et al., 2005), where L is a nonplanar heterocyclic amine ligand. The cytotoxicity of this last compound is improved compared to transplatin (Khazanov et al., 2002; Najajreh et al., 2003), but the non-activity of trans-Pt(NH3)Cl2(hmpy), trans-Pt(hmpy)2Cl2 and [Pt(hmpy)3Cl]Cl (hmpy is 3- or 4-hydroxymethylpyridine) precludes any generalization.
A few years ago, we undertook a systematic and detailed study of complexes of the type cis- and trans-Pt(Ypy)2X2 (X is Cl-, I- or NO3-) (Tessier & Rochon, 1999, 2001) and their hydrolysis products (Rochon & Tessier, 2002) by various techniques, including multinuclear NMR and X-ray crystallography. The pyridine derivatives included pyridine, the three picoline isomers, 2,4-lutidine and 3,5-lutidine. This series was used to study the steric and ligand basicity effects on the nature of the Pt—Ypy bond, as well as the number of hydrolyzed species in neutral media. As expected, the steric effects preclude formation of hydroxy-bridged oligomers (Rochon & Tessier, 2002). We also observed a relation of the NMR chemical shifts with the pKa of the protonated ligands, indicating that the σ(Ypy→Pt) bond is more important than the π(Pt←Ypy) back-donation. We established the relative position of the ligands in the trans-influence series. In the course of the study, we obtained the title compound, (I), during an attempt to synthesize its cis-isomer. Compound (I) is the first example of an acetylpyridine–platinum complex to be structurally characterized.
Complex (I) is the trans-isomer. cis→trans isomerization in Pt(Ypy)2X2 complexes is not uncommon (Kong & Rochon, 1978; Tessier & Rochon, 1999). The Pt atom lies on a crystallographic inversion center, resulting in an anti arrangement of the 3-acetylpyridine ligands. Table 1 lists the geometric parameters. The Pt—N and Pt—I bond distances are identical to those obtained for other trans-Pt(Ypy)2I2 complexes (Table 2). The bond angles and the coplanarity of the atoms indicate a square-planar geometry around the Pt center. The O atom in the acetyl group does not participate in any hydrogen bonding or long-range contact. The dihedral angle between the pyridine ring and the Pt coordination plane is 67.5 (2)°.
Table 2 lists the dihedral angles for previously reported trans-Pt(Ypy)2I2 complexes, while a more complete list for all square-planar complexes containing the trans-Pt(Ypy)2 moiety, as listed in the Cambridge Structural Database, (CSD, Version 5.27; Allen, 2002), is provided in the supplementary material (Table S1). The value obtained for compound (I) lies between the values obtained for the 3-methylpyridine (63.5°; KARVAA; Tessier & Rochon, 1999) and (3-pyridyl)methane-sulfonamide (69.1°; ACAZOU; Dodoff et al., 2004) complexes (Table 2). Various factors, such as steric hindrance, the other ligands and intermolecular interactions, could influence the orientation of the pyridine rings. As a general rule, ortho-substituted pyridine derivatives are almost perpendicular to the Pt coordination plane [for example, trans-Pt(2-Mepy)2I2 in Table 2]. The other ligands also seem to influence the dihedral angles. The order is as follows (from greater to smaller): I > Cl ~NH3 ~ C≡ C > NO3. The values obtained for the nitrate complexes are noticeably smaller (39–40°; Tessier & Rochon, 2001).
The acetate moiety of (I) is not coplanar with the pyridine ring, as indicated by the dihedral angle of 20.8 (2)° (or see torsion angles in Table 1). This phenomenon is not uncommon for other platinum structures found in the CSD that contain at least one RC(O)-pyridine derivative (Table 3). The first five structures in Table 3 are monosubstituted on the pyridine derivative, the four following are disubstituted and the rest are tetrasubstituted. No general rule can be found, except that values seem to be smaller for monosubstituted complexes. The hydrogen-bonding pattern certainly plays an important role, as it occurs to some extent in all complexes in Table 3, with the exception of trans-Pt(4-(COOEt)py)2Cl2, where the ethoxycarbonyl moiety is almost coplanar with the pyridine ring (1.2°; Camalli et al., 1980). No hydrogen-bonding pattern is observed in (I).
The 195Pt NMR resonance of compound (I) was observed at -3224 p.p.m. This observation is in the expected range for trans-Pt(Ypy)2I2 complexes (-3122 to -3264 p.p.m.; Tessier & Rochon, 1999). The reaction of compound (I) with silver nitrate in acetone (Souchard et al., 1990; Tessier & Rochon, 2001) results in the formation of the trans-Pt(3-Acpy)2(NO3)2 species, as indicated by the 195Pt NMR signal (CDCl3) observed at -1474 p.p.m. The expected values for trans-Pt(Ypy)2(NO3)2 are from -1402 to -1481 p.p.m. (Tessier & Rochon, 2001).
Data collection: XSCANS (Siemens, 1995); cell refinement: XSCANS; data reduction: XSCANS; program(s) used to solve structure: SHELXS97 (Sheldrick, 1997); program(s) used to refine structure: SHELXL97 (Sheldrick, 1997); molecular graphics: SHELXTL (Bruker, 2003); software used to prepare material for publication: SHELXTL.
Fig. 1. A diagram of compound (I) with the atom-labeling scheme. Displacement ellipsoids are drawn at the 50% probability level. |
[PtI2(C7H7NO)2] | F(000) = 624 |
Mr = 691.16 | Dx = 2.652 Mg m−3 |
Monoclinic, P21/c | Mo Kα radiation, λ = 0.71073 Å |
Hall symbol: -P 2ybc | Cell parameters from 22 reflections |
a = 4.632 (1) Å | θ = 2.2–13.6° |
b = 16.456 (5) Å | µ = 11.68 mm−1 |
c = 11.483 (3) Å | T = 292 K |
β = 98.57 (3)° | Platelet, yellow |
V = 865.5 (4) Å3 | 0.31 × 0.10 × 0.04 mm |
Z = 2 |
Siemens P4 diffractometer | 1494 reflections with I > 2σ(I) |
Radiation source: fine-focus sealed tube | Rint = 0.028 |
Graphite monochromator | θmax = 27.5°, θmin = 2.2° |
2θ/ω scans | h = −6→0 |
Absorption correction: integration (XPREP; Bruker, 2003) | k = −21→0 |
Tmin = 0.313, Tmax = 0.631 | l = −14→14 |
2206 measured reflections | 3 standard reflections every 97 reflections |
1970 independent reflections | intensity decay: none |
Refinement on F2 | Primary atom site location: structure-invariant direct methods |
Least-squares matrix: full | Secondary atom site location: difference Fourier map |
R[F2 > 2σ(F2)] = 0.035 | Hydrogen site location: inferred from neighbouring sites |
wR(F2) = 0.078 | H-atom parameters constrained |
S = 1.00 | w = 1/[σ2(Fo2) + (0.0276P)2] where P = (Fo2 + 2Fc2)/3 |
1970 reflections | (Δ/σ)max < 0.001 |
98 parameters | Δρmax = 0.87 e Å−3 |
0 restraints | Δρmin = −0.78 e Å−3 |
[PtI2(C7H7NO)2] | V = 865.5 (4) Å3 |
Mr = 691.16 | Z = 2 |
Monoclinic, P21/c | Mo Kα radiation |
a = 4.632 (1) Å | µ = 11.68 mm−1 |
b = 16.456 (5) Å | T = 292 K |
c = 11.483 (3) Å | 0.31 × 0.10 × 0.04 mm |
β = 98.57 (3)° |
Siemens P4 diffractometer | 1494 reflections with I > 2σ(I) |
Absorption correction: integration (XPREP; Bruker, 2003) | Rint = 0.028 |
Tmin = 0.313, Tmax = 0.631 | 3 standard reflections every 97 reflections |
2206 measured reflections | intensity decay: none |
1970 independent reflections |
R[F2 > 2σ(F2)] = 0.035 | 0 restraints |
wR(F2) = 0.078 | H-atom parameters constrained |
S = 1.00 | Δρmax = 0.87 e Å−3 |
1970 reflections | Δρmin = −0.78 e Å−3 |
98 parameters |
Geometry. All e.s.d.'s (except the e.s.d. in the dihedral angle between two l.s. planes) are estimated using the full covariance matrix. The cell e.s.d.'s are taken into account individually in the estimation of e.s.d.'s in distances, angles and torsion angles; correlations between e.s.d.'s in cell parameters are only used when they are defined by crystal symmetry. An approximate (isotropic) treatment of cell e.s.d.'s is used for estimating e.s.d.'s involving l.s. planes. |
Refinement. Refinement of F2 against ALL reflections. The weighted R-factor wR and goodness of fit S are based on F2, conventional R-factors R are based on F, with F set to zero for negative F2. The threshold expression of F2 > σ(F2) is used only for calculating R-factors(gt) etc. and is not relevant to the choice of reflections for refinement. R-factors based on F2 are statistically about twice as large as those based on F, and R- factors based on ALL data will be even larger. |
x | y | z | Uiso*/Ueq | ||
Pt1 | 0.0000 | 0.0000 | 0.0000 | 0.03634 (12) | |
I1 | 0.33217 (12) | 0.04824 (3) | 0.19118 (4) | 0.04814 (15) | |
N1 | 0.0164 (14) | −0.1154 (4) | 0.0620 (5) | 0.0384 (13) | |
O1 | 0.4735 (16) | −0.2958 (4) | −0.0833 (6) | 0.0726 (19) | |
C2 | 0.1508 (16) | −0.1749 (4) | 0.0096 (6) | 0.0383 (16) | |
H2 | 0.2463 | −0.1614 | −0.0534 | 0.046* | |
C3 | 0.1527 (15) | −0.2547 (4) | 0.0453 (6) | 0.0351 (15) | |
C4 | 0.0141 (17) | −0.2749 (5) | 0.1416 (6) | 0.0424 (17) | |
H4 | 0.0108 | −0.3283 | 0.1682 | 0.051* | |
C5 | −0.1182 (18) | −0.2130 (5) | 0.1962 (7) | 0.0491 (19) | |
H5 | −0.2077 | −0.2244 | 0.2616 | 0.059* | |
C6 | −0.1179 (17) | −0.1358 (5) | 0.1545 (6) | 0.0439 (17) | |
H6 | −0.2135 | −0.0955 | 0.1909 | 0.053* | |
C7 | 0.2979 (18) | −0.3172 (5) | −0.0218 (6) | 0.0457 (18) | |
C8 | 0.213 (2) | −0.4039 (5) | −0.0139 (8) | 0.065 (2) | |
H8A | 0.3677 | −0.4380 | −0.0325 | 0.098* | |
H8B | 0.0389 | −0.4142 | −0.0686 | 0.098* | |
H8C | 0.1769 | −0.4155 | 0.0646 | 0.098* |
U11 | U22 | U33 | U12 | U13 | U23 | |
Pt1 | 0.0495 (2) | 0.02541 (17) | 0.03624 (19) | 0.0038 (2) | 0.01324 (15) | 0.00082 (17) |
I1 | 0.0585 (3) | 0.0408 (3) | 0.0453 (3) | 0.0025 (3) | 0.0083 (2) | −0.0036 (2) |
N1 | 0.047 (3) | 0.032 (3) | 0.037 (3) | 0.003 (3) | 0.008 (3) | 0.003 (2) |
O1 | 0.079 (5) | 0.063 (4) | 0.083 (4) | 0.001 (4) | 0.037 (4) | −0.016 (4) |
C2 | 0.041 (4) | 0.032 (4) | 0.042 (4) | −0.005 (3) | 0.007 (3) | −0.007 (3) |
C3 | 0.040 (4) | 0.032 (3) | 0.035 (3) | 0.003 (3) | 0.009 (3) | 0.000 (3) |
C4 | 0.049 (4) | 0.036 (4) | 0.044 (4) | −0.006 (4) | 0.011 (3) | 0.005 (3) |
C5 | 0.059 (5) | 0.049 (5) | 0.044 (4) | 0.000 (4) | 0.021 (4) | 0.007 (4) |
C6 | 0.050 (4) | 0.044 (4) | 0.040 (4) | 0.008 (4) | 0.014 (3) | 0.001 (3) |
C7 | 0.061 (5) | 0.038 (4) | 0.041 (4) | 0.004 (4) | 0.015 (4) | 0.001 (3) |
C8 | 0.095 (7) | 0.037 (4) | 0.065 (5) | 0.009 (5) | 0.016 (5) | 0.001 (4) |
Pt1—N1 | 2.026 (6) | C4—C5 | 1.386 (11) |
Pt1—I1 | 2.6097 (10) | C4—H4 | 0.9300 |
N1—C2 | 1.349 (9) | C5—C6 | 1.358 (11) |
N1—C6 | 1.351 (9) | C5—H5 | 0.9300 |
O1—C7 | 1.206 (9) | C6—H6 | 0.9300 |
C2—C3 | 1.375 (10) | C7—C8 | 1.486 (11) |
C2—H2 | 0.9300 | C8—H8A | 0.9600 |
C3—C4 | 1.400 (9) | C8—H8B | 0.9600 |
C3—C7 | 1.503 (10) | C8—H8C | 0.9600 |
N1—Pt1—I1 | 90.19 (17) | C6—C5—H5 | 119.8 |
N1—Pt1—I1i | 89.81 (17) | C4—C5—H5 | 119.8 |
C2—N1—C6 | 117.9 (6) | N1—C6—C5 | 122.3 (7) |
C2—N1—Pt1 | 121.3 (5) | N1—C6—H6 | 118.9 |
C6—N1—Pt1 | 120.7 (5) | C5—C6—H6 | 118.9 |
N1—C2—C3 | 122.9 (6) | O1—C7—C8 | 121.6 (8) |
N1—C2—H2 | 118.5 | O1—C7—C3 | 119.5 (7) |
C3—C2—H2 | 118.5 | C8—C7—C3 | 118.8 (7) |
C2—C3—C4 | 118.6 (7) | C7—C8—H8A | 109.5 |
C2—C3—C7 | 119.0 (6) | C7—C8—H8B | 109.5 |
C4—C3—C7 | 122.4 (7) | H8A—C8—H8B | 109.5 |
C5—C4—C3 | 117.9 (7) | C7—C8—H8C | 109.5 |
C5—C4—H4 | 121.0 | H8A—C8—H8C | 109.5 |
C3—C4—H4 | 121.0 | H8B—C8—H8C | 109.5 |
C6—C5—C4 | 120.3 (7) | ||
I1—Pt1—N1—C2 | −113.5 (5) | C7—C3—C4—C5 | −178.8 (7) |
I1i—Pt1—N1—C2 | 66.5 (5) | C3—C4—C5—C6 | 1.6 (12) |
I1—Pt1—N1—C6 | 69.2 (6) | C2—N1—C6—C5 | 0.8 (11) |
I1i—Pt1—N1—C6 | −110.8 (6) | Pt1—N1—C6—C5 | 178.1 (6) |
C6—N1—C2—C3 | 0.9 (11) | C4—C5—C6—N1 | −2.1 (13) |
Pt1—N1—C2—C3 | −176.4 (5) | C2—C3—C7—O1 | 19.7 (11) |
N1—C2—C3—C4 | −1.3 (11) | C4—C3—C7—O1 | −161.5 (8) |
N1—C2—C3—C7 | 177.5 (7) | C2—C3—C7—C8 | −158.1 (8) |
C2—C3—C4—C5 | 0.0 (11) | C4—C3—C7—C8 | 20.6 (11) |
Symmetry code: (i) −x, −y, −z. |
Experimental details
Crystal data | |
Chemical formula | [PtI2(C7H7NO)2] |
Mr | 691.16 |
Crystal system, space group | Monoclinic, P21/c |
Temperature (K) | 292 |
a, b, c (Å) | 4.632 (1), 16.456 (5), 11.483 (3) |
β (°) | 98.57 (3) |
V (Å3) | 865.5 (4) |
Z | 2 |
Radiation type | Mo Kα |
µ (mm−1) | 11.68 |
Crystal size (mm) | 0.31 × 0.10 × 0.04 |
Data collection | |
Diffractometer | Siemens P4 |
Absorption correction | Integration (XPREP; Bruker, 2003) |
Tmin, Tmax | 0.313, 0.631 |
No. of measured, independent and observed [I > 2σ(I)] reflections | 2206, 1970, 1494 |
Rint | 0.028 |
(sin θ/λ)max (Å−1) | 0.649 |
Refinement | |
R[F2 > 2σ(F2)], wR(F2), S | 0.035, 0.078, 1.00 |
No. of reflections | 1970 |
No. of parameters | 98 |
H-atom treatment | H-atom parameters constrained |
Δρmax, Δρmin (e Å−3) | 0.87, −0.78 |
Computer programs: XSCANS (Siemens, 1995), XSCANS, SHELXS97 (Sheldrick, 1997), SHELXL97 (Sheldrick, 1997), SHELXTL (Bruker, 2003), SHELXTL.
Pt1—N1 | 2.026 (6) | C3—C7 | 1.503 (10) |
Pt1—I1 | 2.6097 (10) | C7—C8 | 1.486 (11) |
O1—C7 | 1.206 (9) | ||
N1—Pt1—I1 | 90.19 (17) | O1—C7—C3 | 119.5 (7) |
N1—Pt1—I1i | 89.81 (17) | C8—C7—C3 | 118.8 (7) |
O1—C7—C8 | 121.6 (8) | ||
C2—C3—C7—O1 | 19.7 (11) | C2—C3—C7—C8 | −158.1 (8) |
C4—C3—C7—O1 | −161.5 (8) | C4—C3—C7—C8 | 20.6 (11) |
Symmetry code: (i) −x, −y, −z. |
CSD refcode | Ypy | Pt—N | Pt—I | Dihedral angle | Reference |
KARVEE | 2-Mepy | 2.024 | 2.614 | 81.9 | (a) |
2.055 | 2.616 | 89.9 | (a) | ||
DIPYPT | Py | 2.035 | 2.597 | 74.0 | (b) |
KARTUS | 4-Mepy | 2.017 | 2.603 | 70.4 | (a) |
ACAZOU | 3-(NHSO2Me)py | 2.032 | 2.607 | 69.1 | (c) |
KARVAA | 3-Mepy | 2.020 | 2.604 | 63.5 | (a) |
References: (a) Tessier & Rochon (1999). (b) Thiele & Wagner (1978). (c) Dodoff et al. (2004). |
at least one C(O)R-pyridine derivative top
CSD refcode | Compound | Dihedral angle | Reference |
MUYBEN | [Pt(4-(COOH)py)(Ph2MeP)2(Ph)](OTf) | 3.9 | (a) |
MUYBIR | [Pt(4-(COOH)py)(PEt3)2(Ph)](OTf) | 11.4 | (a) |
TEXFEH | [Pt(4-(COOH)py)(2,6-(MeMet)py)](ClO4)a | 5.6 | (b) |
XURDIX | Pt(3-(COO)2-hypy)(PPh3)2Clb | 1.9 | (c) |
FOQXAK | Pt(2-(COO)3-hypy)(PPh3)2Clc | 3.7 | (d) |
CLPRPT | trans-Pt(4-(COOEt)py)2Cl2 | 1.2 | (e) |
NIXMIQ | trans-Pt(3-(CONHR)py)2Cl2d | 33.4 | (f) |
XIKJEG | cis-[Pt(4-(CONH2)py)2(PEt3)2](NO3)2 | 21.0; 33.5 | (g) |
JOSDAW01 | cis-[Pt(4-(CONH2)py)2(NH3)2](NO3)2 | 25.7 | (h) |
GOKMOI | Pt(4-(COO)py)2(4-(COOH)py)2 | 3.2-21.0 | (i) |
GOKMIC | [Pt(4-(CONH2)py)4]Cl2e | 12.0; 21.8 | (i) |
XAYKUD | [Pt(4-(CONH2)py)4]Cl2f | 33.9 | (j) |
XAYLAK | [Pt(4-(CONH2)py)4](PF6)2 | 7.6-38.4 | (j) |
JOQSOX | [Pt(3-(CONH2)py)4]Cl2 | 20.0; 40.4 | (k) |
JOQSUD | [Pt(3-(CONH2)py)4](PF6)2 | 1.8; 8.4 | (k) |
QEXLAG | [Pt(3-(CONHBu)py)4](PF6)2 | 14.0 | (l) |
QEXLEK | [Pt(3-(CONHBu)py)4](ReO4)2 | 19.2 | (l) |
a2,6-(MeMet)py = 2,6-bis(methylthiomethyl)pyridine. b3-(COO)2-hypy = 2-hydroxynicotinate. c2-(COO)3-hypy = 3-hydroxypicolinato. d3-(CONHR)py = N-nitroxyethylnicotinamide. etetrakis(4-aldoximepyridine)clathrate. f = heptahydrate. References: (a) Crisp et al. (2003). (b) Marangoni et al. (1996). (c) Quintal et al. (2002). (d) Quintal et al. (2000). (e) Camalli et al. (1980). (f) Eremenko et al. (1997). (g) Kuehl et al. (2001). (h) Minacheva et al. (1991). (i) Aakeroy et al. (1999). (j) Brammer et al. (2000). (k) Mareque Rivas & Brammer (1998). (l) Bondy et al. (2001). |
Subscribe to Acta Crystallographica Section C: Structural Chemistry
The full text of this article is available to subscribers to the journal.
- Information on subscribing
- Sample issue
- Purchase subscription
- Reduced-price subscriptions
- If you have already subscribed, you may need to register
The anticancer drug cisplatin, cis-Pt(NH3)2Cl2, and a few other platinum agents are widely used in the clinical treatment of testicular, ovarian, bladder, head and neck tumors (Farrell, 1989; O'Dwyer et al., 1999). Structure–activity rules that emerged from early studies include the assessment that trans complexes are therapeutically inactive, as opposed to cis complexes – a rule based mainly on the lack of activity for transplatin. Some exceptions from this paradigm were found in 1989, including trans-Pt(pyridine)2Cl2 (Farrell et al., 1989), which is even active towards leukemia L1210 cisplatin-resistant cell lines (Van Beusichem & Farrell, 1992). A review of the cytotoxicity of trans-platinum complexes has been published recently (Natile & Coluccia, 2001).
Platinum–pyridine derivative compounds not only gained interest because of this rule-breaking finding, but also due to the recently reported anticancer complex cis-PtCl2(NH3)(2-picoline) (AMD473) (Chen et al., 1998; Holford et al., 1998). This compound, active both via oral administration and injection, is currently in phase II clinical trials. Other than AMD473 itself and its trans-isomer (McGowan et al., 2005), recent studies involving platinum complexes containing pyridine derivatives (Ypy) include Pt(ESDT)(Ypy)(NH3)Cl (Marzano et al., 2002, 2004; Giovagnini et al., 2005), in which the ethylsarcosinedithiocarbamate ligand (ESDT) is used to reduce nephrotoxic effects, Pt(OAc)2(Ypy)2 and Pt(OAc)2(Ypy)(NH3) (Ma et al., 2005; Quiroga et al., 2006), in which the acetate ligands were used in order to obtain water-soluble complexes, and trans-PtCl2(4-pic)L (Najajreh et al., 2005), where L is a nonplanar heterocyclic amine ligand. The cytotoxicity of this last compound is improved compared to transplatin (Khazanov et al., 2002; Najajreh et al., 2003), but the non-activity of trans-Pt(NH3)Cl2(hmpy), trans-Pt(hmpy)2Cl2 and [Pt(hmpy)3Cl]Cl (hmpy is 3- or 4-hydroxymethylpyridine) precludes any generalization.
A few years ago, we undertook a systematic and detailed study of complexes of the type cis- and trans-Pt(Ypy)2X2 (X is Cl-, I- or NO3-) (Tessier & Rochon, 1999, 2001) and their hydrolysis products (Rochon & Tessier, 2002) by various techniques, including multinuclear NMR and X-ray crystallography. The pyridine derivatives included pyridine, the three picoline isomers, 2,4-lutidine and 3,5-lutidine. This series was used to study the steric and ligand basicity effects on the nature of the Pt—Ypy bond, as well as the number of hydrolyzed species in neutral media. As expected, the steric effects preclude formation of hydroxy-bridged oligomers (Rochon & Tessier, 2002). We also observed a relation of the NMR chemical shifts with the pKa of the protonated ligands, indicating that the σ(Ypy→Pt) bond is more important than the π(Pt←Ypy) back-donation. We established the relative position of the ligands in the trans-influence series. In the course of the study, we obtained the title compound, (I), during an attempt to synthesize its cis-isomer. Compound (I) is the first example of an acetylpyridine–platinum complex to be structurally characterized.
Complex (I) is the trans-isomer. cis→trans isomerization in Pt(Ypy)2X2 complexes is not uncommon (Kong & Rochon, 1978; Tessier & Rochon, 1999). The Pt atom lies on a crystallographic inversion center, resulting in an anti arrangement of the 3-acetylpyridine ligands. Table 1 lists the geometric parameters. The Pt—N and Pt—I bond distances are identical to those obtained for other trans-Pt(Ypy)2I2 complexes (Table 2). The bond angles and the coplanarity of the atoms indicate a square-planar geometry around the Pt center. The O atom in the acetyl group does not participate in any hydrogen bonding or long-range contact. The dihedral angle between the pyridine ring and the Pt coordination plane is 67.5 (2)°.
Table 2 lists the dihedral angles for previously reported trans-Pt(Ypy)2I2 complexes, while a more complete list for all square-planar complexes containing the trans-Pt(Ypy)2 moiety, as listed in the Cambridge Structural Database, (CSD, Version 5.27; Allen, 2002), is provided in the supplementary material (Table S1). The value obtained for compound (I) lies between the values obtained for the 3-methylpyridine (63.5°; KARVAA; Tessier & Rochon, 1999) and (3-pyridyl)methane-sulfonamide (69.1°; ACAZOU; Dodoff et al., 2004) complexes (Table 2). Various factors, such as steric hindrance, the other ligands and intermolecular interactions, could influence the orientation of the pyridine rings. As a general rule, ortho-substituted pyridine derivatives are almost perpendicular to the Pt coordination plane [for example, trans-Pt(2-Mepy)2I2 in Table 2]. The other ligands also seem to influence the dihedral angles. The order is as follows (from greater to smaller): I > Cl ~NH3 ~ C≡ C > NO3. The values obtained for the nitrate complexes are noticeably smaller (39–40°; Tessier & Rochon, 2001).
The acetate moiety of (I) is not coplanar with the pyridine ring, as indicated by the dihedral angle of 20.8 (2)° (or see torsion angles in Table 1). This phenomenon is not uncommon for other platinum structures found in the CSD that contain at least one RC(O)-pyridine derivative (Table 3). The first five structures in Table 3 are monosubstituted on the pyridine derivative, the four following are disubstituted and the rest are tetrasubstituted. No general rule can be found, except that values seem to be smaller for monosubstituted complexes. The hydrogen-bonding pattern certainly plays an important role, as it occurs to some extent in all complexes in Table 3, with the exception of trans-Pt(4-(COOEt)py)2Cl2, where the ethoxycarbonyl moiety is almost coplanar with the pyridine ring (1.2°; Camalli et al., 1980). No hydrogen-bonding pattern is observed in (I).
The 195Pt NMR resonance of compound (I) was observed at -3224 p.p.m. This observation is in the expected range for trans-Pt(Ypy)2I2 complexes (-3122 to -3264 p.p.m.; Tessier & Rochon, 1999). The reaction of compound (I) with silver nitrate in acetone (Souchard et al., 1990; Tessier & Rochon, 2001) results in the formation of the trans-Pt(3-Acpy)2(NO3)2 species, as indicated by the 195Pt NMR signal (CDCl3) observed at -1474 p.p.m. The expected values for trans-Pt(Ypy)2(NO3)2 are from -1402 to -1481 p.p.m. (Tessier & Rochon, 2001).